MJH Life Sciencestm Hosts Pharma CEO Roundtable on Market Impact of COVID-19
Hosted by its popular industry brand, Pharmaceutical Executive®,MJH Life Sciencestmorganized a closed virtual roundtable, "Pharmaceutical CEO Leadership During the Pandemic."
The roundtable brought together the CEOs of 11 pharmaceutical companies, representing start-up biotech and small to midsize pharma companies, to discuss how COVID-19 has impacted their organizations and pharma as a whole, necessitated a shift in tactics and spurred innovation.
"The insights shared by these CEOs offer a glimpse into the future of pharma in the wake of COVID-19, from product launches and working with the FDA to clinical trials and market access," said Mike Hennessy Jr., president and CEO of MJH Life Sciencestm. "Having these leaders come together at this unprecedented time to share their learnings as they work toward a common goal offers a vision of optimism and innovation for the road ahead."
The roundtable included the following CEOs:
James A. Barlow Jr., MBA, president and CEO, ImmunoGenesis Inc.
Liz Barrett, president andCEO, UroGen Pharma Ltd.
Michael Castagna, CEO, MannKind Corporation.
John F. Crowley, chairman and CEO, Amicus Therapeutics Inc.
Hervé Hoppenot, chairman, president and CEO, Incyte Corp.
Michael G. Kauffman, M.D., Ph.D., co-founder and CEO, Karyopharm Therapeutics Inc.
Steven Lo, president andCEO, Zosano Pharma Inc.
Michael M. Morrissey, Ph.D., president andCEO, Exelixis Inc.
Leonard S. Schleifer, M.D., Ph.D., founder, president and CEO, Regeneron Pharmaceuticals Inc.
Clay B. Siegall, Ph.D., chairman, president andCEO, Seattle Genetics Inc.
Tim Whitten, president andCEO, Taiho Oncology Inc.
The information gleaned from the discussion is now available on PharmExec.com and will be published in an upcoming issue.
About MJH Life Sciencestm
MJH Life Sciencestm is the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels, providing health care professionals with the information and resources they need to optimize patient outcomes. MJH combines the reach and influence of its powerful portfolio of digital and print product lines, live events, educational programs and market research with the customization capabilities of a boutique firm. Clients include world-leading pharmaceutical, medical device, diagnostic and biotech companies. For more information, please visit https://www.mjhlifesciences.com/.
About Pharmaceutical Executive®
Pharmaceutical Executive®is a multimedia platform that offers news, opinions, analysis, features and executive profiles. The magazine and its website serve as a forum for industry leaders to exchange opinions, experiences and insights about innovative business and marketing ideas, strategies and tactics. Pharmaceutical Executive®is a brand of MJH Life Sciencestm, the largest privately held, independent, full-service medical media company in North America, dedicated to delivering trusted health care news across multiple channels.
Results
For the year ended January 31, 2024, the Company's revenues decreased by $139,027,000 to $578,945,000 compared to $717,972,000 recorded for the year ended January 31, 2023, a decrease of 19.4%. This decrease is mainly explained by the...
Lendistry announces today that it has been selected to administer the Entertainment Business Interruption Fund Program (BIF) to support small Los Angeles County businesses serving the entertainment industry. This program, created and funded through...
Rocky Mountain Liquor Inc. (the "Company" or "Rocky Mountain"), listed on the TSX Venture Exchange (the "Exchange"), today reported its financial results for the full year and fourth quarter ended December 31, 2023.KEY...
Guanajuato Silver Company Ltd. (the "Company" or "GSilver") announces a brokered, best-efforts Listed Issuer Financing Exemption private placement (the "Offering") consisting of units of the Company (the "Units") at a price of C$0.20 per Unit (the...
Customers Bancorp, Inc. :
First Quarter 2024 Highlights
Q1 2024 net income available to common shareholders was $45.9 million, or $1.40 per diluted share; ROAA was 0.94% and ROCE was 12.08%.
Q1 2024 core earnings* were $46.5 million, or $1.42...
Petrolympic Ltd. (the "Company", TSXV: PCQ) wishes to announce it has completed a non-brokered private placement (the "Offering") of 5,000,000 common shares of the Company on a flow-through basis ("FT Shares") at a price of $0.08 per FT Share, for...